NCT01702740View on ClinicalTrials.gov

A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

PHASE1CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Lupus Erythematosus, CutaneousLupus Erythematosus, Systemic
Interventions
DRUG

1 mg/kg CNTO 136

Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.

DRUG

4 mg/kg CNTO 136

Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.

DRUG

10 mg/kg CNTO 136

Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.

DRUG

Placebo

Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.

All Listed Sponsors
lead

Centocor Research & Development, Inc.

INDUSTRY

NCT01702740 - A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter